Combined halofenate-chlorpropamide was evaluated for the treatment of NIDDM. Four subjects treated with 500 mg/day chlorpropamide were given 500–1000 mg halofenate daily for 48 wk or longer. Fasting plasma glucose fell from 210 ± 16 (± SEM) (11.67 ± 0.89 mM) to 107 ± 10 mg/dl (± SEM) (5.94 ± 0.55 mM), P < 0.005. Twelve additional subjects were entered into a 16-wk double-blind study testing chlorpropamide plus either placebo or halofenate. In the halofenate group, the mean fasting glucose fell from 227 ± 27 (± SEM) (12.61 ± 1.50 mM) and reached 107 ± 19 mg/dl (± SEM) (5.94 ± 1.06 mM) during the fourth month, whereas the placebo groups showed a decrease from 242 ± 22 (± SEM) to 208 ± 29 mg/dl (± SEM) (P < 0.005). In addition, halofenate reduced the height of postprandial glycemic excursions by lowering fasting plasma glucose. When halofenate was used as the only therapy, reduction in fasting plasma glucose was small [179 ± 12 reduced to 142 ± 8 mg/dl (± SEM); 9.94 ± 0.67 mM and 7.89 ± 0.44 mM], P < 0.05.
Skip Nav Destination
Article navigation
Original Articles|
January 01 1984
Improved Control of Non-insulin-dependent Diabetes Mellitus by Combined Halofenate and Chlorpropamide Therapy
E Alan Kohl, M.D.;
E Alan Kohl, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
James A Magner, M.D.;
James A Magner, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
Scott T Persellin, M.D.;
Scott T Persellin, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
George M Vaughan, M.D.;
George M Vaughan, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
David J Kudzma, M.D.;
David J Kudzma, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
Samuel J Friedberg, M.D.
Samuel J Friedberg, M.D.
Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, the Audie L. Murphy Veterans' Administration Hospital
San Antonio, Texas
and the Albert Einstein College of Medicine
New York, New York
Search for other works by this author on:
Address reprint requests to Samuel J. Friedberg, M.D., Division of Endocrinology and the Department of Medicine, The University of Texas Health Science Center, 7703 Floyd Curl Drive, San Antonio, Texas 78284.
Citation
E Alan Kohl, James A Magner, Scott T Persellin, George M Vaughan, David J Kudzma, Samuel J Friedberg; Improved Control of Non-insulin-dependent Diabetes Mellitus by Combined Halofenate and Chlorpropamide Therapy. Diabetes Care 1 January 1984; 7 (1): 19–24. https://doi.org/10.2337/diacare.7.1.19
Download citation file: